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Abbreviations  
95%CI  95% confidence intervall 
AA  abiraterone acetate 
ADT  androgen deprivation therapy 
AE  adverse event 
ATC  Anatomical Therapeutic Chemical classification system 
BPI-SF  Brief Pain Inventory - Short Form 
BRCA1  Breast Cancer 1 susceptibility protein 
BRCA2  Breast Cancer 2 susceptibility protein 
CRPC  Castration-resistant prostate cancer 
CYP17  cytochrome P450 17 enzyme 
ECOG-PS Eastern Cooperative Oncology Group Performance Status 
EMA  European Medicines Agency 
FACT-P Functional Assessment of Cancer Therapy-Prostate Quality of Life questionnaire 
FDA  Food and Drug Administration 
HR  hazard ratio 
LHRH  luteinizing hormone-releasing hormone 
mCRPC  metastatic castration-resistant prostate cancer 
mg  milligram 
mg/d  milligram per day 
n  number 
NA  not available 
NCI CTCAE v3.0 Common Terminology Criteria for Adverse Events of the National Cancer Institute version 3.0  
ng/dL  nanogramm per decilitre 
ng/mL  nanogramm per milliilitre 
OS  overall survival 
PFS  progression-free survival 
plac  placebo  
pred  prednisone 
PSA  prostate-specific antigen 
PSAWG  Prostate Specific Antigen Working Group 
QoL  quality of life 
RECIST  Response Evaluation Criteria in Solid Tumours 
TNM system Tumour/Node/Metastasis stating system of malignant tumours 
TTPSA  Time to PSA progression 
US  United States of America 
vs  versus 
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1 Drug description 
Generic/Brand name/ATC code:  
Abiraterone acetate/Zytiga™/L02BX03 
Developer/Company:  
Ortho Biotech Oncology Research & Development, Unit of Cougar Biotech-
nology, Inc., marketed Janssen-Cilag 
Description:  
Proliferation and survival of prostate cancer cells depends on signalling 
from the activated androgen receptor. Deprivation of gonadal androgen (i.e. 
androgen produced in the testes), either by surgical or medical castration, is 
thus an initially effective treatment for metastatic prostate cancer [1]. But 
prostate cancer becomes inevitably castration-resistant by several 
mechanisms, for example by overexpression of the cytochrome P450 17 
enzyme (CYP17), the 17α-hydroxylase/C17,20-lyase which regulates the 
androgen biosynthesis in the testes, but also in the adrenal glands and in the 
prostate [2-4]. By overexpression of CYP17 the androgen-receptor signalling 
is maintained, but abiraterone acetate (AA), a new molecular entity, inhibits 
CYP17. 
Capsules containing 250 mg AA are available. The recommended dose is 
1,000 mg/d orally in combination with 5 mg prednisone administered orally 
twice daily. Prednisone is administered to avoid side-effects such as hyper-
tension, hypokalaemia, and fluid retention which can occur due to increased 
mineralocorticoid levels. These side-effects are especially problematic for 
patients with an underlying heart disease. Dose modifications are necessary 
for patients with moderate hepatic impairment [5]. 
2 Indication 
AA is indicated for patients with metastatic castration-resistant prostate 
cancer (mCRPC) previously treated with a docetaxel containing regimen.  
 
 
 
over-expression of the 
enzyme CPY17 one 
mechanism for 
development of 
castration-resistant 
prostate cancer 
 
 
 
abiraterone which as 
administered orally 
inhibits CYP17 
median survival for 
patients with 
metastasised tumours is 
1 - 3 years 
 6 LBI-HTA | 2011 
3 Current regulatory status 
The EMA licensed AA in combination with prednisone or prednisolone for 
the treatment of mCRPC in adult men whose disease has progressed on or 
after a docetaxel-based chemotherapy regimen in September 2011 [6]. 
In the US, the FDA approved Zytiga™ in combination with prednisone for 
the treatment of patients with mCRPC who have received prior chemother-
apy containing docetaxel in April 2011 [5]. 
4 Burden of disease 
Prostate cancer is the most common cancer in men in developed countries 
and the second most common cancer-related cause of death [7]. Median age 
at diagnosis is 72 years. In Austria, about 4,800 men were newly diagnosed 
with prostate cancer and 1,100 died in 2009 [8]; in Germany, 60,100 men 
were diagnosed and 11,600 died in 2006 [9]. Due to widespread prostate-
specific antigen (PSA) testing, prostate cancer is mostly diagnosed at an ear-
ly, asymptomatic stage of disease, resulting in less than 5% of patients which 
were diagnosed after the tumour has spread  [8]. About 40% of men will 
eventually develop metastases [10]. In Austria, disseminated disease was 
found in about 3.6% of patients, resulting in about 150 patients with metas-
tatic prostate cancer per year [8]. Applying the same numbers to Germany 
would result in about 2,000 patients with disseminated prostate cancer.  
Risk factors for developing prostate cancer include age, ethnicity, family his-
tory, diet and genetic factors such as mutations in BRCA1 and BRCA2 genes 
[11].   
Clinical findings include asymmetric areas of induration or frank nodules in 
the prostate during digital rectal examination, genitourinary symptoms (e.g. 
urinary urgency, nocturia, erectile dysfunctions) and, in the minority of pa-
tients, symptoms of metastatic disease. As prostate cancer mainly metasta-
sises to bones, most common symptoms at this stage are bone pain. To estab-
lish diagnosis of prostate cancer, a histologic examination should be per-
formed [11].    
Staging is done by using the TNM system which provides information for 
choosing the initial therapy. Other factors which impact on the choice of ini-
tial therapy are life expectancy, comorbidities, therapeutic side-effects and 
patients’ preferences [12]. 
Besides the TNM system, the Gleason score is used to establish prognosis. 
This score is a histopathologic grading system which distinguishes well and 
poorly differentiated prostate tissue [12, 13]. By taking the TNM system, the 
Gleason score and pre-treatment PSA levels into account, five patient groups 
with different probabilities of cure can be derived [11].   
Prognosis strongly depends on the stage at diagnosis. If the tumour is con-
fined to the prostate gland, a median survival of more than 5 years can be 
expected. For locally advanced forms of prostate cancer, cure is rarely possi-
EMA licensed 
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FDA in April 2011 
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ble, but median survival is still about 5 years. Patients with metastasised 
tumours have a median survival of 1-3 years [13].    
Castration-resistant prostate cancer refers to prostate cancer which pro-
gresses despite androgen deprivation therapy. Disease progression can either 
be defined as a rise in serum levels of PSA, as progression of pre-existing 
disease and/or as the development of new metastases.  
5 Current treatment 
Metastatic prostate cancer is not curable; therefore the main objective of 
therapy for this stage is to maintain quality-of-life (QoL) and to control the 
disease [11].  Therapy includes: 
 Androgen deprivation therapy (ADT) (synonym: hormone therapy, 
castration) is the standard initial therapy for patients with metastatic 
prostate cancer. Surgical castration (synonym: orchiectomy) or medi-
cal castration using a luteinizing hormone-releasing hormone 
(LHRH) agonist is the optimal ADT. In addition, antiandrogens for 
at least 7 days should be administered either prior to or simultane-
ously to LHRH agonists to patients with metastases who are likely to 
develop symptoms associated with an initial increase in testosterone 
(“flare”) with LHRH-agonists only [7, 13].   
In nearly all cases, disease progresses on ADT. If PSA level rises despite cas-
trate levels of testosterone (serum testosterone <20 ng/dL) the cancer is 
called “castrate-resistant”, “hormone-refractory” or “androgen-independent” 
[11].  Systemic therapy options for men with metastatic prostate cancer are 
then: 
 Multiple and sequential secondary hormone therapies including 
withdrawal of ADT, antiandrogen therapy, cytochrome P450 inhibi-
tors, oestrogens and corticosteroids. Even though no improvements in 
survival have been demonstrated for these therapies, the favourable 
toxicity profile justifies their use before the administration of chemo-
therapies [11, 14]. 
 Chemotherapy: 
 As 1st-line chemotherapy the combination of docetaxel and predni-
sone showed improved overall survival (OS) and improved QoL in 
comparison to mitoxantrone and prednisone [11, 15-19]. Therefore 
docetaxel is the standard of care for the initial chemotherapy in 
men with castration-resistant prostate cancer [11, 14, 16-20].  
 Because the combination of mitoxantrone and prednisone com-
pared with prednisone alone achieved pain reduction in patients 
with bone metastases, mitoxantrone might also be used as 1st -line 
chemotherapy  [11, 12, 14, 19] which is considered appropriate for 
patients with slowly progressing disease and for those who are in-
tolerant to docetaxel [21]. 
 2nd-line chemotherapy needs to be considered after docetaxel ther-
apy has failed. Guidelines are tentative in giving a clear recom-
mendation of what should be applied next. Until recently,  
mitoxantrone and prednisone were considered de facto 2nd-line 
hormone therapy is 
standard initial therapy 
options if disease 
progresses:  
sequential secondary 
hormone therapy  
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chemotherapy, despite its unclear impact on survival [11, 12, 15, 
19]. However, this has changed, because cabazitaxel, a new taxane, 
was licensed in Europe in combination with prednisone or predni-
solone for patients with mCRPC who have previously been treated 
with docetaxel in March 2011 [22]. Regarding OS cabazi-
taxel+pred was superior to mitoxantrone+pred, probably at the 
expenses of QoL, which was not investigated. 
 Immunotherapy with sipuleucel-T, which is not licensed in Eu-
rope, has demonstrated prolonged OS for minimally symptomatic 
patients with castrate-resistant prostate cancer and is therefore in-
dicated for minimally symptomatic/asymptomatic and chemother-
apy-naïve patients [12, 18, 19].    
 Symptom palliation for advanced prostate cancer is mainly done by 
systemic therapy, which includes analgesics, radiation therapy and 
bisphosphonates for bone metastases [13]. 
6 Evidence 
In addition to a free text search including the websites of the EMA and of 
the US FDA, an extensive literature search was conducted in Pubmed, Med-
line, EMBASE and the “Centre for Review and Dissemination Database” on 
the 4th of July 2011.  
Only randomized controlled trials which tested AA in the approved indica-
tion (i.e. in men with mCRPC whose disease has progressed on or after a do-
cetaxel-based chemotherapy regimens) were included in the evaluation of ef-
ficacy. Additionally, the trials had to investigate patient relevant outcomes. 
For the evaluation of safety also uncontrolled trials which tested AA in the 
approved indication regardless of the investigated outcomes were consid-
ered.   
Overall, one phase III trial, the COU-AA-301 trial [23], met the selection cri-
teria for efficacy evaluation. For safety evaluation one further trial, the 
phase II COU-AA-004 trial [24], met the criteria. 
 
sipuleucel-T 
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6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title  
A Phase III, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus 
Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have 
Failed Docetaxel-Based Chemotherapy [6, 23, 25] 
Study identi-
fier 
Study No: COU-AA-301, ClinicalTrials Identifier: NCT00638690;  
EudraCT No: 2007-005837-13 
Funding Cougar Biotechnology 
phase III, multinational, randomized (2:1 ratio), double blind, placebo-controlled Design 
Duration  Enrolment: May 2008 –July 2009 
Median follow-up: 12.8 months 
Cut-off date: interim analysis: January 2010,  
Updated analysis: September 2010  
Hypothesis Superiority 
Intervention 4 tablets 250 mg AA/d + 5 mg prednisone orally twice daily for 28 
days 
Treatment 
groups 
Control 4 tablets placebo/d + 5 mg prednisone orally twice daily for 28 days
Overall survival 
(primary outcome) 
OS time from randomization to death from any cause 
Progression-free  
survival 
(pre-specified  
radiographic  
criteria) 
R-PFS Per investigator’s assessment of progression by soft tissue 
(according to modified RECIST criteria [26][baseline 
lymph node ≥2.0 centimetre to be considered target le-
sion],  
or progression by bone scans with ≥2 new lesions not 
consistent with tumour flare. 
PSA response rate 
(pre-specified 
PSAWG criteria) 
PSA-
RESP 
PSA decline of ≥50% confirmed by a second PSA decline 
at least 4 weeks later. 
Time to PSA  
progression 
(pre-specified  
PSAWG criteria) 
TTPSA 1) in patients in whom the PSA level had not decreased, 
PSA progression was defined as a 25% increase over the 
baseline and an increase in the absolute-value PSA level 
by at least 5 ng/mL, which was confirmed by a second 
value;  
2) in patients in whom the PSA had decreased but had not 
reached response criteria [PSA ≤50%], progressive dis-
ease would be considered to have occurred when the PSA 
level increased 25% over the nadir, provided that the in-
crease was a minimum of 5 ng/mL and was confirmed;  
3) and if at least a 50% decrease in the PSA level had been 
achieved, PSA progression would be an increase of 50% 
above the nadir at a minimum of 5 ng/mL 
Endpoints 
and  
definitions 
Quality of Life by 
FACT-P score 
QOL_ 
FACT-P
Total score and each subscale score from FACT-P (physical 
well-being, social/family well-being, emotional well-being, 
functional well-being, and prostate cancer subscale) 
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Results and analysis 
Analysis  
description 
Primary analysis on intention-to-treat 
One interim analysis and one final analysis were planned after observing 534 and 797 
death events, respectively; distributions of time-to-event variables and associated 95%CI 
were estimated with the use of the Kaplan-Meier product–limit method; stratified log-
rank test was used as primary analysis for comparison of treatment groups. 
Characteristics Median age (range): AA+pred 69 years (42 - 95 years) vs 
plac+pred 69 years (39 - 90 years) 
Disease location: Bone AA+pred 89% vs plac+pred 90%;  
Node AA+pred 45% vs plac+pred 41%; Liver AA+pred 11% vs 
plac+pred 8% 
BPI-SF score for pain: AA+pred 3.0 vs plac+pred 3.0 
1 previous chemotherapy: AA+pred 70% vs plac+pred 69% 
2 previous chemotherapies: AA+pred 30% vs plac+pred 31% 
ECOG-PS 0 or 1: AA+pred 90% vs plac+pred 89% 
ECOG-PS 2: AA+pred 10% vs plac+pred 11%: 
Median PSA range (ng/mL): AA+pred 128.8 vs plac+pred 
137.7 
Inclusion previously treated with docetaxel, disease progression,  
ECOG-PS ≤2 
Analysis pop-
ulation 
Exclusion abnormal aminotransferase levels, serious coexisting non-
malignant disease, active or symptomatic viral hepatitis or 
chronic liver disease, uncontrolled hypertension, a history of 
pituitary or adrenal dysfunction, clinically significant heart 
disease, or previous therapy with ketoconazole 
Treatment group Intervention 
(AA+pred) 
Control 
(plac+pred) 
Number of subjects 797 398 
OS, months 
Interim survival analysis: 
median (95%CI)[23] 
 
Updated survival analysis:
median (95%CI) [6] 
 
 
14.8 (14.1 – 15.4) 
 
15.8 (14.8 – 17.0) 
 
 
10.9 (10.2 – 12.0) 
 
11.2 (10.4 – 13.1) 
Median R-PFS, months 
[23] 
5.6 3.6 
PSA_RESP, % [23] 29.1 5.5 
TTPSA, months [23] 10.2 6.6 
Descriptive 
statistics and  
estimated 
variability 
 
 
 
 
 
 
 
QOL_FACT-P NA NA 
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Comparison groups  Intervention vs Control 
(AA+pred versus plac+pred) 
HR 0.65 
95%CI 0.54 to 0.77 
OS (primary analysis) 
P value  <0.001 
HR 0.74 
95%CI 0.64 to 0.86 
OS (updated analysis)  
P value NA 
HR 0.67 
95%CI 0.58 to 0.78 
R-PFS  
P value  <0.001 
PSA_RESP P value <0.001 
TTPSA HR 0.58 
 95%CI 0.46 to 0.73 
Effect  
estimate per  
comparison 
 P value  <0.001 
Notes  Pursuant to the independent data and safety monitoring committee recommendation on 
August 20, 2010, all patients will be unblinded and patients who have received placebo 
will be offered cross-over therapy with AA [25]. 
Horizon Scanning in Oncology 
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Table 2: Adverse events with a frequency of >25% (regarding all grades), >5 (regarding grade 3), >1% (regarding 
grade 4) in either treatment arm 
COU-AA-301 trial 
Grade  
(according to 
NCI CTCAE v3.0 
[27] 
Outcome 
number of patients (%) 
Intervention 
(AA+pred)  
(n= 791) 
Control 
(plac+pred) 
(n=394) 
All grades Fatigue 346 (44) 169 (43) 
 Fluid retention and oe-
dema 
241 (31) 88 (22) 
 Back pain 233 (30) 129 (33) 
 Nausea  233 (30) 124 (32) 
 Arthralgia 215 (27) 89 (23) 
 Bone pain 195 (25) 110 (28) 
 Constipation 106 (26) 120 (31) 
 Vomiting 168 (21) 97 (25) 
 Anaemia 178 (23) 104 (26) 
Grade 3 Fatigue 64 (8) 36 (9) 
 Anaemia 51 (6) 23 (6) 
 Back pain 44( 6) 37 (9) 
 Bone pain 42 (5) 25 (6 ) 
 Pain in arm or leg 18 (2) 20 (5) 
Grade 4 Anaemia 8 (1) 6 (2) 
 Cardiac disorders  7 (1) 2 (<1) 
 Bone pain 2 (<1) 4 (1) 
Grade 5 AEs leading to death NA (12) NA (15) 
 Fatal cardiac events NA (1.1) NA (1.3) 
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797 patients with progressive mCRPC after previous docetaxel therapy were 
randomised to receive AA+pred and 398 were allocated to the plac+ pred 
group [23]. Patients were stratified according to ECOG-PS, pain level, num-
ber of previous chemotherapies and type of evidence of disease progression. 
The median duration of treatment was 8 months for the AA+pred group and 
4 months for the plac+pred group.  
At a pre-planned interim analysis after 534 deaths had occurred, median OS, 
the primary outcome, was statistically improved in patients treated with 
AA+pred with 14.8 months compared to 10.9 months in the plac+pred 
group (HR = 0.65, p<0.001) [23]. An updated survival analysis conducted in 
September 2010 (i.e. after 97% of the planned number of deaths for final 
analysis had been observed) showed improved outcomes for OS as well (15.8 
vs. 11.2 months, HR = 0.74, 95%CI 0.64 to 0.86) [6]. Focussing on OS, sub-
group analyses according to randomization strata, predefined and one non-
predefined subgroup were conducted of which the results for the strata and 
some of the predefined subgroups were published [25]. These data showed 
consistent results favouring the AA+pred group. Only in one of the pre-
sented subgroups, i.e. the patients with ECOG-PS 2, no significant differ-
ence was found. Yet, no conclusion can be drawn for this subgroups since it 
was small and no confirmatory interaction test was performed.  
Better results were also found for all secondary outcomes, i.e. PFS, TTPSA 
and PSA_RESP [23].  
Many exploratory endpoints were investigated, of which the results of objec-
tive response rate and pain-related outcomes have been published, the latter 
mainly on abstract basis [23, 26]. All demonstrated results in favour of 
AA+pred as, for example, the pain intensity palliation rate was 44% in the 
AA+pred group and 27% in the plac+pred group (p<0.001) [26]. QoL as as 
exploratory endpoint was assessed with the FACT-P questionnaire [25], but 
results have not been published yet. 
In terms of adverse events (AEs), the most frequent one was fatigue of any 
grade, which occurred at similar frequencies in both treatment arms 
(AA+pred 44% vs plac+pred 43%). Side-effects due to the blockade of 
CYP17 and thus due to elevated mineralocorticoid levels (e.g. fluid retention 
+ oedema, hypokalaemia, hypertension) were more frequent in the 
AA+pred group (AA+pred 55% vs. plac+pred 43%, p<0.001). Even though 
cardiac events were more often observed in patients treated with AA+pred 
than with plac+pred, this difference was not significant (13% vs. 11%, 
p=0.22) [23]. Urinary tract infections of any grade occurred more often in 
the AA+pred group (12%) than in the comparison group (7%) (p=0.02); 
and were primarily grade 1 or 2 events. Treatment was discontinued in a 
similar proportion of patients in both arms (AA+pred 19% vs plac+pred 
23%, p=0.09) and 12% died in the AA+pred group due to AEs in compari-
son to 15% in the plac+pred group. 
The independent data and safety monitoring committee recommended un-
blinding the study in August 2010. Patients were then allowed to cross-over 
from the plac+pred group to the active therapy AA+pred arm. 
AA + prednisone vs 
placebo + prednisone 
 
 
 
improved outcomes for 
OS and other endpoints 
in the AA group 
consistent results across 
subgroups  
also better results for 
pain palliation  
AEs manageable 
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6.2 Further studies - safety 
An uncontrolled phase II study, the COU-AA-004 trial, investigated 
AA+pred in 58 patients with mCRPC who had progressed under ADT and 
docetaxel-based chemotherapy [24]. Patients were pre-treated with antian-
drogens, estrogens and ketoconazole. Primary endpoint was PSA response. A 
decline of PSA of ≥50% was confirmed in 36% of patients. No grade 4 AEs 
were observed and those of grade 3 were infrequent. Most common AEs of 
grade 1 or 2 were fatigue (16%) and nausea (14%).  
7 Estimated costs 
No cost estimates for Zytiga™ are available yet in Austria but some hint was 
found that one bottle containing 120 tablets à 250 mg AA is sold for $ 5,000 
(≈ € 3,500) in the US [28] which would also be the monthly treatment costs. 
Since the median duration of treatment in the phase III trial was 8 months 
and one cycle was 28 days, the overall treatment costs for AA are thus an es-
timated € 28,000. 
In Germany the pharmacy retail price for Zytiga™ (N2 package) is € 5,445 
[29] which might officially result in approximately € 5,000. Due to the fact 
that 1,000 mg AA are administered daily, the N2 package (i.e. average sized 
package), which contains 120 tablets à 250 mg AA, covers the treatment for a 
month. Since the median duration of treatment in the phase III pivotal trial 
was 8 months, the overall treatment costs for AA are an estimated € 40,000. 
8 On-going research 
Regarding the investigated indication no further on-going RCT was identi-
fied.  
In chemotherapy-naïve patients with mCRPC, however, one additional 
phase III RCT was found on ClinicalTrial.gov.  
 NCT00887198 (the COU-AA-302 trial): is currently on-going and in-
vestigates AA+pred in comparison to plac+pred in asymptomatic or 
mildly symptomatic patients with chemotherapy-naïve mCRPC. The 
estimated study completion date is April 2014, but the final data col-
lection date for the primary outcome measure was April 2011. 
Several other phase I and II studies are currently conducted in different 
stages of prostate cancer (mCRPC, CRPC without metastases, prostate can-
cer not yet hormone-treated, neo-adjuvant setting). Most of them are per-
formed without a control arm and focus on surrogate endpoints only.  
Another indication currently under investigation is breast cancer.  
one further 
uncontrolled phase II 
study… 
no cost estimates for 
Austria 
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9 Commentary  
The EMA has granted market authorization for Zytiga™ in combination with 
prednisone for patients with mCRPC after docetaxel based chemotherapy in 
September 2011 [6]. This decision was based on a pivotal phase III study, 
the COU-AA-301 study, which demonstrated a difference in OS by 3.9 
months for AA+pred in comparison to plac+pred in docetaxel pre-treated 
patients with mCRPC. Due to the findings of this interim analysis the inde-
pendent data and safety monitoring committee recommended un-blinding of 
the study and eligible patients were allowed to cross-over to the active 
treatment arm. AEs related to AA+pred were acceptable and mostly compa-
rable to those observed in the plac+pred group, although statistically sig-
nificant differences in favour for the placebo group were found for AEs asso-
ciated with increased mineralocorticoid levels, but they were mainly of grade 
1 or 2 [6]. QoL data were assessed, yet results have not been fully published. 
Since median follow-up was about 13 months, no data on the long-term us-
age of AA+pred exist.  
Until recently, no therapy with demonstrated benefit of OS after failure of 
docetaxel therapy of patients with mCRPC existed. This has changed lately, 
because Zytiga™ is now, besides cabazitaxel, the 2nd regimen for which im-
provements in OS have been found. For cabazitaxel + prednisone, median 
OS was 15.1 months in comparison to 12.7 months for mitoxantrone + 
prednisone, yielding a HR of 0.70 (p<0.0001) [30]. For AA+pred, median 
OS was 14.8 months in comparison to 10.9 months (p<0.001) for plac+pred, 
resulting in a HR of 0.65. Comparing the risk-profiles of these two drugs, 
foremost haematological side-effects were considerably less frequent in pa-
tients treated with AA+pred, as haematological AEs grade ≥3 occurred in 
up to 97% of patients treated with cabazitaxel+pred and in a maximum of 
6% in the AA+pred group. Frequencies of non-haematological AEs grade 
≥3 were comparable and were observed in 8% in the AA+pred group and in 
6% of patients treated with cabazitaxel+pred.  
Both drugs have already been incorporated into international guidelines or 
are recommended in the US after docetaxel therapy [11, 12]. Even though 
the optimal sequencing of these drugs still remains unknown, AA+pred 
might be preferable over cabazitaxel+pred for patients with slowly progres-
sive disease due to fewer AEs [11]. The “National Comprehensive Cancer 
Care Guidelines” even mention that AA might be used for patients not eligi-
ble for docetaxel therapy. Hence, studies investigating AA in this setting and 
as 1st-line therapy in general are of further interest [12]. 
Besides these two agents, several other agents are currently being tested in 
phase III trials, also assessing patients pre-treated with docetaxel [1, 2, 29]. 
For example, first results for radium-223 chloride (AlpharadinTM) showed 
improvements in OS in comparison to placebo by 2.8 months (HR = 0.695) 
with low toxicity [31]. It is also likely that several of these new drugs will be 
administered sequentially or in combination, foremost, because mCRPC 
will eventually become resistant to AA [1]. Combination therapies are thus 
discussed, involving experimental drugs such as MDV3100 or TOK-001 
which also inhibit androgen receptor signalling [1]. Efforts are therefore in-
creasingly targeted towards predicting response and resistance to certain 
therapies in order to identify subgroups most likely to benefit [32]. Clini-
cians are and will be even more confronted with the challenge of choosing 
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one therapy over the other, without direct evidence of comparative effective-
ness since such trials are resource intense and time-consuming and might 
already be outdated by the time finished. However, one means of selecting 
the best treatment option is to consider a drug’s impact on QoL.  
A positive side-effect of an increasing number of treatment options is that 
health care providers might be enabled to negotiate on costs or can choose a 
therapy by also considering the associated treatment costs. For example, in 
the US cabazitaxel seems to cost about $ 8,000 every three weeks (i.e. one cy-
cle) in comparison to $ 5,000 for one month therapy with AA [33]. In Ger-
many, however, the expenses for one cycle cabazitaxel is about € 5,000 [34], 
which is about the same like for AA. Concerning treatment costs, it should 
also be kept in mind, that, for example, AA+pred is also being investigated 
for chemotherapy-naïve patients and might thus be used in even earlier lines 
of therapies [10], a fact which would increase the eligible population and 
thus the overall costs considerably.  
In conclusion, the landscape for mCRPC therapy is rapidly evolving and 
several agents have shown increased OS for mCRPC after docetaxel therapy. 
The gains of about 4 months in OS, which can be regarded as a relevant im-
provement, in addition to an acceptable safety profile indicate that AA + 
pred is currently the most beneficial therapy. In order to ultimately identify 
the best regimen, reliable data for QoL are needed for all treatment options. 
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